Evidence mapPaperPMID 42449699Full record

ReviewCancers2026

Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery.

Cezary Miedziarek, Paweł Caputa, Hubert Bochyński, Mikołaj Piotr Zaborowski, Ewa Nowak-Markwitz

Abstract readReview
In one paragraph

Review in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cezary MiedziarekDivision of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.ORCID 0000-0002-1933-7530
Paweł CaputaDivision of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Hubert BochyńskiDivision of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.
Mikołaj Piotr ZaborowskiDivision of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.ORCID 0000-0002-4400-6688
Ewa Nowak-MarkwitzDivision of Gynecological Oncology, Department of Gynecology, Poznan University of Medical Sciences, 61-701 Poznań, Poland.ORCID 0000-0002-2009-2040

Funding

Foundation for Polish Science FENG.02.02-IP.05-0361/23National Agency for Academic Exchange PPI/STE/2020/1/00014/DEC/02
6 · The paper itself

Abstract

Cytoreductive surgery remains one of the key treatment modalities in advanced ovarian cancer. Complete cytoreduction is the main surgical goal. PARP inhibitors are currently established mainly as maintenance therapy after response to platinum-based chemotherapy, particularly in patients with

Indexed as

complete cytoreductioncytoreductive surgeryneoadjuvant therapyovarian cancerPARP inhibitors

Identifiers

PMID42449699
PMCPMC13360071

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.